Jump Financial LLC Increases Holdings in 10x Genomics $TXG

Key Points

• Jump Financial LLC increased its holdings in 10x Genomics by 144.3% in the 1st quarter, owning 452,282 shares valued at $3,948,000 at the quarter's end.
• 10x Genomics reported a revenue of $172.91 million in its last quarter, surpassing analyst estimates of $139.36 million, along with earnings of $0.28 per share.
• Research analysts have mixed ratings for the stock, with consensus indicating a Hold rating and a target price of $13.54.

Jump Financial LLC lifted its position in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 144.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 452,282 shares of the company's stock after acquiring an additional 267,181 shares during the quarter. Jump Financial LLC owned 0.37% of 10x Genomics worth $3,948,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. AlphaQuest LLC boosted its stake in shares of 10x Genomics by 8.3% during the 1st quarter. AlphaQuest LLC now owns 29,459 shares of the company's stock worth $257,000 after acquiring an additional 2,258 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in shares of 10x Genomics during the 1st quarter worth approximately $420,000. Fox Run Management L.L.C. purchased a new stake in shares of 10x Genomics during the 1st quarter worth approximately $270,000. Russell Investments Group Ltd. boosted its stake in shares of 10x Genomics by 385.6% during the 1st quarter. Russell Investments Group Ltd. now owns 81,669 shares of the company's stock worth $713,000 after acquiring an additional 64,851 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of 10x Genomics during the 1st quarter worth approximately $1,755,000. Hedge funds and other institutional investors own 84.68% of the company's stock.

10x Genomics Stock Performance

TXG stock opened at $14.07 on Tuesday. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $24.76. The stock's 50 day moving average price is $12.65 and its 200 day moving average price is $10.62. The firm has a market cap of $1.75 billion, a P/E ratio of -20.10 and a beta of 2.03.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The company had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. During the same quarter in the prior year, the company posted ($0.32) EPS. The business's revenue for the quarter was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. On average, research analysts predict that 10x Genomics will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Stephens reissued an "overweight" rating and set a $14.00 price target on shares of 10x Genomics in a research note on Thursday, May 15th. JPMorgan Chase & Co. decreased their price target on 10x Genomics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. The Goldman Sachs Group decreased their price target on 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research note on Monday, May 12th. Bank of America upped their target price on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Thursday, June 26th. Finally, Barclays reaffirmed an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $13.54.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.